Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 73

1.

Targeting the Microenvironment in High Grade Serous Ovarian Cancer.

Nwani NG, Sima LE, Nieves-Neira W, Matei D.

Cancers (Basel). 2018 Aug 10;10(8). pii: E266. doi: 10.3390/cancers10080266. Review.

2.

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.

Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP.

Clin Cancer Res. 2018 Jul 1;24(13):3163-3175. doi: 10.1158/1078-0432.CCR-18-0204. Epub 2018 Apr 3.

PMID:
29615458
3.

Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.

Özeş AR, Pulliam N, Ertosun MG, Yılmaz Ö, Tang J, Çopuroğlu E, Matei D, Özeş ON, Nephew KP.

Oncogene. 2018 Jun;37(26):3589-3600. doi: 10.1038/s41388-018-0218-z. Epub 2018 Mar 26.

PMID:
29576612
4.

Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.

Condello S, Sima L, Ivan C, Cardenas H, Schiltz G, Mishra RK, Matei D.

Cancer Res. 2018 Jun 1;78(11):2990-3001. doi: 10.1158/0008-5472.CAN-17-2319. Epub 2018 Mar 6.

PMID:
29510995
5.

A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.

Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, Nephew KP, Jueliger S, Oganesian A, Naim S, Su XY, Keer H, Azab M, Fleming GF.

Clin Cancer Res. 2018 May 15;24(10):2285-2293. doi: 10.1158/1078-0432.CCR-17-3055. Epub 2018 Mar 2.

PMID:
29500276
6.

Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.

Fang F, Cardenas H, Huang H, Jiang G, Perkins SM, Zhang C, Keer HN, Liu Y, Nephew KP, Matei D.

Cancer Res. 2018 Feb 1;78(3):631-644. doi: 10.1158/0008-5472.CAN-17-1492. Epub 2017 Dec 11.

PMID:
29229600
7.

Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells.

Li J, Condello S, Thomes-Pepin J, Ma X, Xia Y, Hurley TD, Matei D, Cheng JX.

Cell Stem Cell. 2017 Mar 2;20(3):303-314.e5. doi: 10.1016/j.stem.2016.11.004. Epub 2016 Dec 29.

8.

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.

Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U.

Br J Cancer. 2016 Nov 22;115(11):1313-1320. doi: 10.1038/bjc.2016.348. Epub 2016 Nov 8.

9.

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.

Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.

PMID:
27617661
10.

EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.

Cardenas H, Zhao J, Vieth E, Nephew KP, Matei D.

Oncotarget. 2016 Dec 20;7(51):84453-84467. doi: 10.18632/oncotarget.11497.

11.

Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.

de Leon M, Cardenas H, Vieth E, Emerson R, Segar M, Liu Y, Nephew K, Matei D.

Gynecol Oncol. 2016 Sep;142(3):539-47. doi: 10.1016/j.ygyno.2016.06.017. Epub 2016 Jun 30.

12.

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.

Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA.

Cancer. 2016 Jun 15;122(12):1844-52. doi: 10.1002/cncr.29995. Epub 2016 Apr 8.

13.

NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.

Özeş AR, Miller DF, Özeş ON, Fang F, Liu Y, Matei D, Huang T, Nephew KP.

Oncogene. 2016 Oct 13;35(41):5350-5361. doi: 10.1038/onc.2016.75. Epub 2016 Apr 4.

14.

Development of Follicle-Stimulating Hormone Receptor Binding Probes to Image Ovarian Xenografts.

Lee CW, Guo L, Matei D, Stantz K.

J Biotechnol Biomater. 2015 Sep;5(3). pii: 198. Epub 2015 Sep 10.

15.

Intracellular Doppler Signatures of Platinum Sensitivity Captured by Biodynamic Profiling in Ovarian Xenografts.

Merrill D, An R, Sun H, Yakubov B, Matei D, Turek J, Nolte D.

Sci Rep. 2016 Jan 6;6:18821. doi: 10.1038/srep18821.

16.

Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.

Benson EA, Skaar TC, Liu Y, Nephew KP, Matei D.

PLoS One. 2015 Oct 20;10(10):e0141279. doi: 10.1371/journal.pone.0141279. eCollection 2015.

17.

Concurrent Detection of Cellular and Molecular Cancer Markers Using an Immunomagnetic Flow System.

Huang W, Chang CL, Chan BD, Jalal SI, Matei DE, Low PS, Savran CA.

Anal Chem. 2015 Oct 20;87(20):10205-12. doi: 10.1021/acs.analchem.5b02215. Epub 2015 Jul 24.

PMID:
26165381
18.

In vivo tumor growth of high-grade serous ovarian cancer cell lines.

Mitra AK, Davis DA, Tomar S, Roy L, Gurler H, Xie J, Lantvit DD, Cardenas H, Fang F, Liu Y, Loughran E, Yang J, Sharon Stack M, Emerson RE, Cowden Dahl KD, V Barbolina M, Nephew KP, Matei D, Burdette JE.

Gynecol Oncol. 2015 Aug;138(2):372-7. doi: 10.1016/j.ygyno.2015.05.040. Epub 2015 Jun 5.

19.

TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells.

Cardenas H, Vieth E, Lee J, Segar M, Liu Y, Nephew KP, Matei D.

Epigenetics. 2014 Nov;9(11):1461-72. doi: 10.4161/15592294.2014.971608.

20.

High-dose chemotherapy for recurrent ovarian germ cell tumors.

Reddy Ammakkanavar N, Matei D, Abonour R, Einhorn LH.

J Clin Oncol. 2015 Jan 10;33(2):226-7. doi: 10.1200/JCO.2014.59.4325. Epub 2014 Dec 1. No abstract available.

PMID:
25452440

Supplemental Content

Loading ...
Support Center